Application of physiologically-based pharmacokinetic model approach to predict pharmacokinetics and drug-drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine
- PMID: 36193622
- PMCID: PMC9662201
- DOI: 10.1002/psp4.12844
Application of physiologically-based pharmacokinetic model approach to predict pharmacokinetics and drug-drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine
Abstract
Rivaroxaban (RIV; Xarelto; Janssen Pharmaceuticals, Beerse, Belgium) is one of the direct oral anticoagulants. The drug is a strong substrate of cytochrome P450 (CYP) enzymes and efflux transporters. This study aimed to develop a physiologically-based pharmacokinetic (PBPK) model for RIV. It contained three hepatic metabolizing enzyme reactions (CYP3A4, CYP2J2, and CYP-independent) and two active transporter-mediated transfers (P-gp and BCRP transporters). To illustrate the performance of the developed RIV PBPK model on the prediction of drug-drug interactions (DDIs), carbamazepine (CBZ) was selected as a case study due to the high DDI potential. Our study results showed that CBZ significantly reduces the exposure of RIV. The area under the concentration-time curve from zero to infinity (AUCinf ) of RIV was reduced by 35.2% (from 2221.3 to 1438.7 ng*h/ml) and by 25.5% (from 2467.3 to 1838.4 ng*h/ml) after the first dose and at the steady-state, respectively, whereas the maximum plasma concentration (Cmax ) of RIV was reduced by 37.7% (from 266.3 to 166.1 ng/ml) and 36.4% (from 282.3 to 179.5 ng/ml), respectively. The developed PBPK model of RIV could be paired with PBPK models of other interested perpetrators to predict DDI profiles. Further studies investigating the extent of DDI between CBZ and RIV should be conducted in humans to gain a full understanding of their safety and effects.
© 2022 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Conflict of interest statement
The authors declared no competing interests in this work.
Figures





Similar articles
-
Application of the Population Pharmacokinetics Model-Based Approach to the Prediction of Drug-Drug Interaction between Rivaroxaban and Carbamazepine in Humans.Pharmaceuticals (Basel). 2023 May 2;16(5):684. doi: 10.3390/ph16050684. Pharmaceuticals (Basel). 2023. PMID: 37242468 Free PMC article.
-
Development and verification of a physiologically based pharmacokinetic model of dronedarone and its active metabolite N-desbutyldronedarone: Application to prospective simulation of complex drug-drug interaction with rivaroxaban.Br J Clin Pharmacol. 2023 Jun;89(6):1873-1890. doi: 10.1111/bcp.15670. Epub 2023 Feb 7. Br J Clin Pharmacol. 2023. PMID: 36683488
-
Pharmacokinetics and Drug-Drug Interaction of Ocedurenone (KBP-5074) in vitro and in vivo.Eur J Drug Metab Pharmacokinet. 2023 Jul;48(4):397-410. doi: 10.1007/s13318-023-00837-5. Epub 2023 Jun 25. Eur J Drug Metab Pharmacokinet. 2023. PMID: 37357226 Free PMC article.
-
Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling.Arch Pharm Res. 2017 Dec;40(12):1356-1379. doi: 10.1007/s12272-017-0976-0. Epub 2017 Oct 27. Arch Pharm Res. 2017. PMID: 29079968 Review.
-
Investigating Intestinal Transporter Involvement in Rivaroxaban Disposition through Examination of Changes in Absorption.Pharm Res. 2021 May;38(5):795-801. doi: 10.1007/s11095-021-03039-3. Epub 2021 Apr 13. Pharm Res. 2021. PMID: 33847849 Free PMC article.
Cited by
-
Optimization of wet granulation process for manufacturing Rivaroxban generic immediate-release tablets using PBPK modeling and simulations.In Silico Pharmacol. 2024 Aug 22;12(2):77. doi: 10.1007/s40203-024-00249-6. eCollection 2024. In Silico Pharmacol. 2024. PMID: 39184229
-
Development of a physiologically-based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady-state conditions.CPT Pharmacometrics Syst Pharmacol. 2025 Mar;14(3):523-539. doi: 10.1002/psp4.13293. Epub 2024 Dec 23. CPT Pharmacometrics Syst Pharmacol. 2025. PMID: 39714044 Free PMC article.
-
Effect of the frequently used antiepileptic drugs carbamazepine, gabapentin, and pregabalin on the pharmacokinetics of edoxaban and other oral factor xa inhibitors in healthy volunteers.Front Pharmacol. 2025 Apr 11;16:1542063. doi: 10.3389/fphar.2025.1542063. eCollection 2025. Front Pharmacol. 2025. PMID: 40290437 Free PMC article.
-
Applying Physiologically Based Pharmacokinetic Modeling to Interpret Carbamazepine's Nonlinear Pharmacokinetics and Its Induction Potential on Cytochrome P450 3A4 and Cytochrome P450 2C9 Enzymes.Pharmaceutics. 2024 May 30;16(6):737. doi: 10.3390/pharmaceutics16060737. Pharmaceutics. 2024. PMID: 38931859 Free PMC article.
-
Application of the Population Pharmacokinetics Model-Based Approach to the Prediction of Drug-Drug Interaction between Rivaroxaban and Carbamazepine in Humans.Pharmaceuticals (Basel). 2023 May 2;16(5):684. doi: 10.3390/ph16050684. Pharmaceuticals (Basel). 2023. PMID: 37242468 Free PMC article.
References
-
- Bayer Pharma AG Xarelto (rivaroxaban) Summary of Product Characteristics ; 2013. https://www.ema.europa.eu/en/documents/product‐information/xarelto‐epar‐...
-
- European Medicines Agency . CHMP assessment report for Xarelto ; 2008. https://www.ema.europa.eu/en/documents/assessment‐report/xarelto‐epar‐pu...
-
- Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In vitro and in vivo P‐glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther. 2011;338:372‐380. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous